Immunocore gets FDA breakthrough nod for eye melanoma drug ahead of planned Q3 filing

Immunocore has received FDA breakthrough-therapy designation for tebentafusp in unresectable or metastatic uveal melanoma. The British biotech snagged the status ahead of a planned filing for FDA approval in the third quarter.